VISAGE: Impacts of Two Rehabilitation Programs on Chronic Peripheral Facial Paresis

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Recruiting
CT.gov ID
NCT04074018
Collaborator
(none)
82
3
2
28.8
27.3
0.9

Study Details

Study Description

Brief Summary

Introduction: Peripheral facial paresis (PFP) is a very common disease of various etiologies affecting average adults with no predominance of sex. In 70% of cases, motor recovery is rapid and complete, but in 30% of early PFP, motor symptoms such as paresis and/or abnormal movements (synkinesis, contractures and/or spasms) can live on and jeopardize patients quality of life at medium and even long term. Concerning therapeutic interventions, the rehabilitation patient care of PFP is often restricted to the early stage. A recent randomized controlled study showed that early rehabilitation had a positive impact on motor recovery, specifically in severe motor grades, and could also accelerate time of recovery without exacerbating synkinesis. At chronic stage of the pathology, there is no controlled study testing the effect of motor rehabilitation when deficiencies are often considered as fitted and permanents.

Objective: It is well known in other domains that intensive motor strengthening increases cerebral plasticity in general, and particularly that of sensorimotor command. The main hypothesis of the study is that motor strengthening even at chronic stage of PFP could increase motor function and decrease abnormal motor movements through a self-rehabilitation motor program. The main objective is thus to compare the clinical, kinematic and quality-of-life related impacts of two different rehabilitation programs on motor recovery in unilateral PFP at chronic stage (i.e. at least 1 year after injury): a self-rehabilitation program guided by Physical Medicine and Rehabilitation (PMR) therapist versus facial rehabilitation involving physiotherapist or speech therapist specialized in facial rehabilitation. The main evaluation criterion is the evolution of the Sunnybrook Facial Grading Scale composite score between Day0 (before rehabilitation) and Day180 (after 6 months of facial rehabilitation).

Method: National, Randomized simple blind controlled study, in two parallel groups: Both program have to be realized daily for 6 months (Day1 to Day180). The population is made of adults with unilateral PFP at chronic stage i.e. at least 1 year from injury. Evaluations and follow-up of patients will be accomplished in a single center: Service de Rééducation Neurolocomotrice de l'Hôpital Mondor in Créteil (France).

Condition or Disease Intervention/Treatment Phase
  • Other: Self-rehabilitation program
  • Other: Conventional rehabilitation program
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
82 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants are assigned to one of two groups, using computerized randomization, for the duration of the study in each center.Participants are assigned to one of two groups, using computerized randomization, for the duration of the study in each center.
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Clinical, Kinematic and Quality-of-life Related Impacts of Two Rehabilitation Programs in Chronic Peripheral Facial Paresis: a Randomized Control Trial.
Actual Study Start Date :
Jan 4, 2021
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental group

Self-rehabilitation guided program with investigator PMR specialist

Other: Self-rehabilitation program
facial self-rehabilitation for a duration of 6 months

Active Comparator: Control group

Conventional rehabilitation with a speech therapist or physiotherapist specialized in facial rehabilitation

Other: Conventional rehabilitation program
Conventional facial rehabilitation for a duration of 6 months

Outcome Measures

Primary Outcome Measures

  1. Change of Composite score of the Sunnybook Facial Grading System [Day 0 and Day 180]

    estimation of resting symmetry (score 0 to 20), symmetry at voluntary movement (score 20 to 100) and synkinesis (score 0 to 15) composite score = symmetry at voluntary movement - resting symmetry - synkinesis from Day 0 to Day 180. (Ross et al. 1996, PMID: 8649870)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > 17 yo;

  • Ambulatory patient;

  • Motivation to participate to a rehabilitative facial program for six months;

  • Patient consent to shaving (men) and no makeup (women) in order not to hamper evaluations the morning of the 4 visits of the study ;

  • Signed informed consent;

  • Affiliation to asocial security scheme.

Exclusion Criteria:
  • Peripheral facial paresis of evolving tumoral etiology;

  • Medical history of botulinum toxin injections in facial muscles during the last 6 months preceding inclusion or injections planned during the study;

  • Medical history of facial surgery in the last two years preceding inclusion or planned during the study;

  • Medical history of facial reanimation surgery needing specific rehabilitation (V-VII or XII-VII anastomosis or muscle transfer);

  • Medical history of medical aesthetic facial treatments (hyaluronic acid/ lipofilling/laser/bracing wires) in the preceding two years before inclusion or planned during the study;

  • Recurrent PFP;

  • Implication in other research interventional protocol dealing with aesthetical aspect of the face or with PFP;

  • Intercurrent pathology impeding the realization of the rehabilitation program during the study;

  • Cognitive, mental or psychiatric troubles impeding the realization of the rehabilitation program or the capacity to attend both evaluations and follow-up consultations;

  • Tutorship or guardianship patient.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Intercommunal de Créteil Créteil Val De Marne France 94010
2 Hôpital Henri Mondor Créteil Val De Marne France 94010
3 Hôpital Saint-Joseph Paris France 75014

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

  • Principal Investigator: Marjolaine BAUDE, MD, APHP CHU HENRI MONDOR

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT04074018
Other Study ID Numbers:
  • K170105J
First Posted:
Aug 29, 2019
Last Update Posted:
Jun 14, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 14, 2022